Creating AI tools to predict vascular disease risk and progression
Official title: Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression
Run by Amsterdam UMC, location VUmc · NCT06206369 · Data updated 2026-11-12
This study is trying to create smart computer tools that can predict the risk and progression of vascular diseases like abdominal aortic aneurysm and peripheral arterial disease by looking at medical images and patient history.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 90 Years |
| Sex | All |
| Enrollment | 11000 (estimated) |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Locations | 6 sites (Helsinki and 5 other locations) |
| Status | Recruiting |
| Started | October 31, 2023 |
| Main results expected | May 1, 2029 |
| Study ends | May 1, 2029 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT06206369 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are males and females aged 40-90 with an AAA greater than 3cm or any stage of PAD.
✕Probably not a fit
Patients with ascending, thoracic, or thoracoabdominal aneurysms will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The VASCULAID-RETRO study aims to develop artificial intelligence algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). By analyzing data from at least 5000 AAA and 6000 PAD patients, the study will utilize existing cohorts and retrospectively collected data. The AI tools will perform automatic anatomical segmentation and analyses on multimodal imaging, while prediction algorithms will be based on a combination of imaging, medical history, and -omics data. This innovative approach seeks to enhance the understanding of disease progression and risk assessment in vascular conditions.
Why it matters
Potential benefit: If successful, this study could significantly improve the ability to predict cardiovascular events and disease progression in patients with AAA and PAD.
How similar studies have gone: Other studies utilizing AI for predicting vascular disease risk have shown promise, indicating a potential for success in this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria AAA: * Males and females * 40-90 years old, * Infrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter), and mycotic aneurysms. * Starting AAA diameter \>3cm, * Patients that both have had or did not have interventions or ruptures. Exclusion Criteria AAA: * Patients with solely an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm. Inclusion Criteria PAD: * Males and females, * 40-90 years old, * All PAD patients; all Fontaine stages 1,2,3, and 4. Exclusion Criteria PAD: None
Where it's running
-
Hospital District of Helsinki and Uusimaa (HUS)
Helsinki, Finland Recruiting -
Asklepios kliniken hamburg
Hamburg, Germany Recruiting -
Amsterdam UMC
Amsterdam, Netherlands Recruiting -
University Hospital Center of São João
Porto, Portugal Recruiting -
University Clinical Centre of Serbia
Belgrade, Serbia Recruiting -
Oxford University Hospitals
Oxford, United Kingdom Recruiting
Study contacts
- Study coordinator: Kak Khee Yeung, MD, PhD
- Email: k.yeung@amsterdamumc.nl
- Phone: +31 6 14278725
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
Predictors of Major Adverse Limb Events After Iliac Artery Stenting
This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Radial and Ulnar Access in Vascular Interventions Registry
This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.
-
Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease
This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.
-
Imaging plaque activity across the body in people with symptomatic peripheral arterial disease
This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.